BioAge Labs Management
Management criteria checks 2/4
BioAge Labs' CEO is Kristen Fortney, appointed in Apr 2015, has a tenure of 11.33 years. total yearly compensation is $2.89M, comprised of 20.8% salary and 79.2% bonuses, including company stock and options. directly owns 2.13% of the company’s shares, worth €9.05M. The average tenure of the management team and the board of directors is 5.6 years and 2.5 years respectively.
Key information
Kristen Fortney
Chief executive officer
US$2.9m
Total compensation
| CEO salary percentage | 20.79% |
| CEO tenure | 11.3yrs |
| CEO ownership | 2.1% |
| Management average tenure | 5.6yrs |
| Board average tenure | 2.5yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$94m |
| Mar 31 2026 | n/a | n/a | -US$90m |
| Dec 31 2025 | US$3m | US$600k | -US$81m |
| Sep 30 2025 | n/a | n/a | -US$76m |
| Jun 30 2025 | n/a | n/a | -US$79m |
| Mar 31 2025 | n/a | n/a | -US$71m |
| Dec 31 2024 | US$12m | US$521k | -US$71m |
| Sep 30 2024 | n/a | n/a | -US$71m |
| Jun 30 2024 | n/a | n/a | -US$62m |
| Mar 31 2024 | n/a | n/a | -US$66m |
| Dec 31 2023 | US$1m | US$493k | -US$64m |
Compensation vs Market: Kristen's total compensation ($USD2.89M) is above average for companies of similar size in the German market ($USD1.04M).
Compensation vs Earnings: Kristen's compensation has been consistent with company performance over the past year.
CEO
Kristen Fortney (42 yo)
Dr. Kristen Fortney, Ph D., is Executive Officer of Retro Biosciences, Inc. Dr. Kristen Fortney is Member of Scientific Advisory Board of Humanity Inc. Dr. Fortney serves as Member of Advisory Board at Kno...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 11.3yrs | US$2.89m | 2.13% € 8.9m | |
| Co-Founder | 11.6yrs | US$1.45m | 0.15% € 611.0k | |
| Chief Medical Officer & Executive VP of Research | 6.3yrs | US$1.48m | no data | |
| Chief Financial Officer | 4.8yrs | no data | 0.080% € 332.4k | |
| Senior Vice President of Finance & Accounting | no data | no data | 0% € 0 | |
| Senior Vice President of Research | no data | no data | no data | |
| Senior Vice President of People | 4.6yrs | no data | no data | |
| Chief Business Officer & Therapeutic Area Head of Brain Aging | 7.4yrs | no data | no data | |
| Chief Strategy Officer | 5.6yrs | no data | no data | |
| Chief Development Officer | 4.8yrs | no data | no data | |
| Senior Vice President of Clinical Science | 4.6yrs | no data | no data | |
| SVP of Technical Operations | no data | no data | no data |
Experienced Management: Y7G's management team is seasoned and experienced (5.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 11.3yrs | US$2.89m | 2.13% € 8.9m | |
| Co-Founder | 9.2yrs | US$1.45m | 0.15% € 611.0k | |
| Independent Director | 2.5yrs | US$137.75k | 0% € 0 | |
| Independent Chairman of the Board | 2yrs | US$172.75k | 0% € 0 | |
| Independent Director | 2.5yrs | US$129.25k | 0% € 0 | |
| Independent Director | 9.2yrs | US$114.01k | no data | |
| Independent Director | 2.4yrs | US$138.75k | 0% € 0 | |
| Member of Scientific & Metabolic Advisory Board | 2.3yrs | no data | no data | |
| Member of Scientific & Metabolic Advisory Board | 2.3yrs | no data | no data | |
| Member of Scientific & Metabolic Advisory Board | 2.3yrs | no data | no data | |
| Independent Director | 5yrs | US$141.75k | 0.0065% € 27.3k | |
| Member of Scientific & Metabolic Advisory Board | 2.3yrs | no data | no data |
Experienced Board: Y7G's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/13 21:50 |
| End of Day Share Price | 2026/08/13 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioAge Labs, Inc. is covered by 11 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Shrader | BTIG |
| Samantha Lynn Semenkow | Citigroup Inc |
| Salveen Richter | Goldman Sachs |